Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13788599 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL351356 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL1536845 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL165641 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL16134189 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL1766170 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL16134190 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL1766172 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL22771166 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 | |
| SCHEMBL17776284 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160208298-A1 | ENZYMATIC PROCESS FOR THE REGIOSELECTIVE MANUFACTURING OF N-FMOC-DOXORUBICIN-14-O-DICARBOXYLIC ACID MONO ESTERS | AETERNA ZENTARIS GMBH (DE) | 2016-07-21 | — | — | US | claimed |
| EP-3045540-A1 | Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters | Æterna Zentaris GmbH (DE) | 2016-07-20 | — | — | EP | claimed |
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| EP-4382167-A2 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | Tagworks Pharmaceuticals B.V. (NL) | 2024-06-12 | — | — | EP | disclosed |
| EP-3788032-B1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-01-24 | — | — | EP | disclosed |
| US-11834480-B2 | Protein inhibitors with reduced immunogenicity and resistance to degradation, and methods for their preparation and use | Amide Technologies (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-02-23 | — | — | US | disclosed |
| EP-4073062-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-10-19 | — | — | EP | disclosed |
| CN-114787148-A | Functionalized heterocyclic compounds as modulators of interferon gene Stimulators (STING) | 雷沃医疗有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220119464-A1 | PROTEIN INHIBITORS WITH REDUCED IMMUNOGENICITY AND RESISTANCE TO DEGRADATION, AND METHODS FOR THEIR PREPARATION AND USE | Amide Technologies (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220056002-A1 | PHOTOCLEAVABLE LINKER FOR CATCHING AND/OR RELEASING OF CIRCULATING TUMOR CELLS OR EXTRA CELLULAR VESICLES | THE UNIVERSITY OF KANSAS (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3045540-A1 | Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters | Æterna Zentaris GmbH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2016-06-23 | — | — | US | disclosed |
| US-9241967-B2 | Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction | UNIVERSITY OF COPENHAGEN (DK) | 2016-01-26 | — | — | US | disclosed |
| EP-2320927-B1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIV COPENHAGEN (DK) | 2015-06-10 | — | — | EP | disclosed |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2011-07-21 | — | — | US | disclosed |
| EP-2320927-A2 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | University of Copenhagen (DK) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010004003-A2 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | UNIVERSITY OF COPENHAGEN (DK) | 2010-01-14 | — | — | WO | disclosed |
| US-6498156-B2 | TREATING HYPERLIPIDEMIA, ARTERIOSCLEROSIS AND HYPERCHOLESTEROLEMIA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-24 | — | — | US | disclosed |
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056002-A1 | PHOTOCLEAVABLE LINKER FOR CATCHING AND/OR RELEASING OF CIRCULATING TUMOR CELLS OR EXTRA CELLULAR VESICLES | EXOSC10, ADAM10, HCCS | LMNA 106/4885EGLN1 248/4885ALKBH5 1676/4885 |
| US-20160176924-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | PSD, GRIN1, GRIN3B | LMNA 3985/4885EGLN1 3729/4885ALKBH5 3139/4885 |
| US-20110178022-A1 | MODIFIED PEPTIDES AS POTENT INHIBITORS OF THE PSD-95/NMDA RECEPTOR INTERACTION | GRIN1, PSD, GRIN3B | LMNA 3871/4885EGLN1 3617/4885ALKBH5 2929/4885 |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | LMNA 3884/4885EGLN1 2696/4885ALKBH5 2427/4885 |
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | LMNA 1165/4885EGLN1 2190/4885ALKBH5 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.